Sage Journals: Discover world-class research

Abstract

Background:

Limited research has evaluated the consumer usability of written information available with similar over-the-counter (OTC) products in different countries. This study evaluated the usability of labels and leaflets for Australian and UK OTC diclofenac products and explored consumer perspectives on their design, content, usability, and potential improvements.

Methods:

Australian and UK OTC diclofenac products were selected for user testing. Demographically matched groups of Australian and UK consumers were recruited to user test each label and leaflet set to determine whether 9 salient clinical messages could be found and understood. Consumer perspectives on the tested label and leaflet were explored using semi-structured interviews as part of user testing.

Results:

Forty consumers user tested the Voltaren Rapid 25 (Australia) and Voltarol Pain-eze Extra Strength 25-mg tablets (UK) information (10 participants per brand per country). Dosage, maximum daily dose, and contraindications information was found and understood by most (≥9/10 per group), except the Voltaren dosage which was misunderstood by 4/20. However, 12/20 could not locate the maximum duration of continuous use in the Voltaren leaflet. Participants had difficulty determining that another nonsteroidal anti-inflammatory drug could not be used with diclofenac (7/20 and 9/20 understood this in the Voltaren and Voltarol groups, respectively). Suggested label and leaflet improvements included increased font size, bolding/highlighting, and color.

Conclusion:

When evaluated in both countries, not all key clinical information was effectively communicated by information accompanying Australian and UK diclofenac products. Improvements in how information is communicated are needed.

Keywords

user testing nonprescription drugs drug labeling medication safety consumers

Get full access to this article

View all access options for this article.

References

Medicines and Healthcare products Regulatory Agency. Medicines: reclassify your product. https://www.gov.uk/guidance/medicines-reclassify-your-product. Published December 18, 2014. Accessed May 6, 2016.

Australian Government Department of Health Therapeutic Goods Administration. Poisons Standard July 2016: Schedule 1—Standard for the Uniform Scheduling of Medicines and Poisons No. 13, Australia. https://www.legislation.gov.au/Details/F2016L01071. Accessed September 24, 2016.

Bolaños

. Responsible self-medication in Latin America. Drug Inf J. 2005;39:99–107.

European Commission. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Brussels: European Commission; 2001.

Australian Government Department of Health Therapeutic Goods Administration. Therapeutic Goods Order No. 69—General requirements for labels for medicines. https://www.legislation.gov.au/Details/F2014C00926. Accessed September 24, 2016.

New South Wales Government. Poisons and Therapeutic Goods Regulation 2008. http://www.legislation.nsw.gov.au/inforce/a24253a9-82f5-4c65-957d-096fb162a62d/2008-392.pdf. Accessed September 24, 2016.

Aslani

. Consumer medicine information conundrums. Aust Prescr. 2007;30:122–124.

Tong

Raynor

Aslani

. Design and comprehensibility of over-the-counter product labels and leaflets: a narrative review. Int J Clin Pharm. 2014;36:865–872.

Raynor

Knapp

Silcock

Parkinson

Feeney

. “User-testing” as a method for testing the fitness-for-purpose of written medicine information. Patient Educ Couns. 2011;83:404–410.

10.

Raynor

. User testing in developing patient medication information in Europe. Res Soc Adm Pharm. 2013;9:640–645.

11.

Sless

Shrensky

. Writing About Medicines for People: Usability Guidelines for Consumer Medicine Information. 3rd ed. Sydney, NSW: Australian Self-Medication Industry; 2006.

12.

European Commission. Guideline on the readability of the labelling and package leaflet of medicinal products for human use Revision 1, 12 January 2009. Brussels: European Commission. http://ec.europa.eu/health/files/eudralex/vol-2/c/2009_01_12_readability_guideline_final_en.pdf. Accessed September 24, 2016.

13.

Communication Research Institute of Australia. Labelling Code of Practice: Designing Usable Non-prescription Medicine Labels for Consumers. Canberra, ACT: Communication Research Institute of Australia; 2004.

14.

Medicines and Healthcare products Regulatory Agency. Best practice guidance on the labelling and packaging of medicines. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/474366/Best_practice_guidance_labelling_and_packaging_of_medicines.pdf. Accessed September 24, 2016.

15.

Jay

Aslani

Raynor

. User testing of consumer medicine information in Australia. Health Educ J. 2011;70:420–427.

16.

Medicines and Healthcare products Regulatory Agency. Oral diclofenac presentations with legal status ‘P’—reclassified to POM. https://www.gov.uk/drug-device-alerts/drug-alert-oral-diclofenac-presentations-with-legal-status-p-reclassified-to-pom. Published January 14, 2015. Accessed September 24, 2016.

17.

Australian Government Department of Health Therapeutic Goods Administration. Safety review of diclofenac version 2.1, October 2014. ACT: Therapeutic Goods Administration. https://www.tga.gov.au/sites/default/files/medicines-review-safety-diclofenac.pdf. Accessed September 24, 2016.

18.

Luk

Tasker

Raynor

DKT

Aslani

. Written medicine information from English-speaking countries—how does it compare? Ann Pharmacother. 2010;44:285–294.

19.

Raynor

Svarstad

Knapp

. Consumer medication information in the United States, Europe, and Australia: a comparative evaluation. J Am Pharm Assoc (2003). 2007;47:717–724.

20.

Pires

Cavaco

. Exploring the perspectives of potential consumers and healthcare professionals on the readability of a package insert: a case study of an over-the-counter medicine. Eur J Clin Pharmacol. 2014;70:583–588.

21.

Voltaren® Rapid 25 [package insert]. Mulgrave, VIC: Novartis Consumer Health Australasia Pty Ltd; 2008.

22.

Voltarol® Pain-eze Extra Strength 25 mg tablets [package insert]. Horsham, UK: Novartis Consumer Health; 2011.

23.

Voltaren® Rapid 25 (10 tablets). Novartis Consumer Health Australasia Pty Ltd; n.d.

24.

Voltarol® Pain-eze Extra Strength 25 mg tablets (10 tablets). Novartis Consumer Health; n.d.

25.

Sansom

, ed. Australian Pharmaceutical Formulary and Handbook: The Everyday Guide to Pharmacy Practice. 22nd ed. Canberra, ACT: Pharmaceutical Society of Australia; 2012.

26.

Australian Medicines Handbook. Adelaide, SA: Australian Medicines Handbook Pty Ltd; 2012.

27.

Tong

Raynor

Aslani

. ‘It’s all there in black and white’ – or is it? Consumer perspectives on the proposed Australian Medicine Information Box over-the-counter label format. Health Expect. 2016;19:948–961.

28.

Aslani

Hamrosi

Feletto

. Investigating Consumer Medicine Information (I-CMI) Project. Sydney, NSW: The Pharmacy Guild of Australia, Australian Government Department of Health and Ageing; 2010.

29.

Chew

Griffin

Partin

. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med. 2008;23:561–566.

30.

Green

Thorogood

. Qualitative Methods for Health Research. 3rd ed. London, UK: Sage Publications; 2014.

31.

Miles

Huberman

. Qualitative Data Analysis: An Expanded Sourcebook. 2nd ed. Thousand Oaks, CA: Sage Publications; 1994.

32.

Tong

Raynor

Aslani

. User testing as a method for identifying how consumers say they would act on information related to over-the-counter medicines. Res Soc Adm Pharm. 2017;13:476–484.

33.

Wolf

Davis

Shrank

. To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns. 2007;67:293–300.

34.

Nabors

Lehmkuhl

Parkins

Drury

. Reading about over-the-counter medications. Issues Compr Pediatr Nurs. 2004;27:297–305.

35.

Blom

ATG

Rens

JAL

. Information about over-the-counter medication: the role of the pharmacy. Patient Educ Couns. 1989;14:181–189.

36.

Hamrosi

Aslani

Raynor

. Beyond needs and expectations: identifying the barriers and facilitators to written medicine information provision and use in Australia. Health Expect. 2014;17:220–231.

37.

Fuchs

Hippius

. Inappropriate dosage instructions in package inserts. Patient Educ Couns. 2007;67:157–168.

38.

Dickinson

Raynor

Duman

. Patient information leaflets for medicines: using consumer testing to determine the most effective design. Patient Educ Couns. 2001;43:147–159.

39.

King

Davis

Bailey

. Developing consumer-centered, nonprescription drug labeling: a study in acetaminophen. Am J Prev Med. 2011;40:593–598.

40.

Sleath

Rubin

Campbell

Gwyther

Clark

. Physician-patient communication about over-the-counter medications. Soc Sci Med. 2001;53:357–369.

41.

Australian Government Department of Health Therapeutic Goods Administration. Consultation: non-steroidal anti-inflammatory drugs (diclofenac, flurbiprofen, ibuprofen, ketoprofen, mefenamic acid and naproxen) for oral use: proposed additional advisory statements for medicines. https://www.tga.gov.au/consultation/consultation-non-steroidal-anti-inflammatory-drugs-diclofenac-flurbiprofen-ibuprofen-ketoprofen-mefenamic-acid-and-naproxen-oral-use-proposed-additional-advisory-statements-medicines. Published February 4, 2015. Accessed May 28, 2016.

42.

Raynor

Dickinson

. Key principles to guide development of consumer medicine information—content analysis of information design texts. Ann Pharmacother. 2009;43:700–706.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.20 MB

Comparative User Testing of Australian and UK Over-the-Counter Labels and Leaflets for Diclofenac

Abstract

Background:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material